The Manila Times

Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today ...
quiverquant

Can-Fite BioPharma Reports H1 2026 Clinical Progress and Financial Results, Including Promising Survival Data in Pancreatic and Liver Cancer Studies

Can-Fite BioPharma reports clinical progress in cancer and psoriasis therapies, alongside H1 2026 financial outcomes.